Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Instituto do Cancer do Estado de São Paulo
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05959720CT.gov Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil | — | Recruiting | — | — | — |
NCT03359694CT.gov Mutation Scores and Differential Protein Evaluating Efficacy in Adjuvant Chemotherapy in HER2(-) Luminal B Breast Cancer | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Chemotherapy-Induced Toxicity
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Adriamycin (this asset) | Instituto do Cancer do Estado de São Paulo | Approved | BB · 65 |
| Dexasone | Instituto do Cancer do Estado de São Paulo | P4 | A |
| Palonosetron | Second Affiliated Hospital, School of Medicine, Zhejiang University | P4 | A |
| Phosphonic Acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-Bis(Trifluoromethyl)Phenyl]Ethoxy]-3-(4-Fluorophenyl)-4-Morpholinyl]Methyl]-2,5-Dihydro-5-Oxo-1H-1,2,4-Triazol-1-Yl]- | Second Affiliated Hospital, School of Medicine, Zhejiang University | P4 | BBB |
| Docetaxel | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | P4 | BB |
| Netupitant | Instituto Brasileiro de Controle do Cancer | P3 | BB |
| HR20013 | Fujian Shengdi Pharmaceutical Co., Ltd. | P3 | BB |
| Carboplatin | Endeavor Health | P3 | BB |
| Ondansetron | Dr Atul Sharma | P3 | BB |
+42 more in the Chemotherapy-Induced Toxicity cohort
Other indications for Adriamycin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 77 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 76 |
| Hematopoietic And Lymphoid System Neoplasm | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- DexasoneInstituto do Cancer do Estado de São PauloA
- PalonosetronSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityA
- Phosphonic Acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-Bis(Trifluoromethyl)Phenyl]Ethoxy]-3-(4-Fluorophenyl)-4-Morpholinyl]Methyl]-2,5-Dihydro-5-Oxo-1H-1,2,4-Triazol-1-Yl]-Second Affiliated Hospital, School of Medicine, Zhejiang UniversityBBB
- DocetaxelThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolBB
- NetupitantInstituto Brasileiro de Controle do CancerBB
Citation
Floatz Terminal. Adriamycin in Chemotherapy-Induced Toxicity. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/adriamycin-chemotherapy-induced-toxicity-114920
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →